CCL12 Inhibitors
CCL12 inhibitors are a class of chemical compounds designed to specifically block the activity of CCL12, a chemokine known for its role in regulating immune cell migration and activation. Chemokines like CCL12 are signaling proteins that guide the movement of immune cells toward areas of inflammation or tissue damage, playing an essential role in immune system regulation and cellular communication. CCL12 inhibitors function by binding to the chemokine itself or by targeting its receptors, which are typically G protein-coupled receptors on the surface of immune cells. By interfering with the interaction between CCL12 and its receptors, these inhibitors prevent the chemokine from triggering downstream signaling pathways that lead to immune cell recruitment and activation.
The structural design of CCL12 inhibitors often involves molecules that can interact with specific binding sites on either the chemokine or its receptors. These inhibitors typically form non-covalent interactions such as hydrogen bonds, hydrophobic interactions, or ionic contacts that stabilize their binding to the target protein. Depending on their mode of action, CCL12 inhibitors may act competitively by directly occupying the binding site of the chemokine, preventing it from interacting with its receptor, or they may work allosterically by binding to secondary sites that induce conformational changes in the chemokine or its receptor. Advanced techniques such as molecular docking, crystallography, and structure-based drug design are used to develop CCL12 inhibitors with high specificity and potency. Through their action, these inhibitors help researchers understand the role of CCL12 in immune system function, shedding light on its involvement in processes such as immune cell trafficking, inflammation, and tissue repair.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone may downregulate CCL12 expression by binding to cytosolic glucocorticoid receptors, which translocate to the cell nucleus and interact with glucocorticoid response elements within the CCL12 gene promoter to suppress gene transcription. | ||||||
Aspirin | 50-78-2 | sc-202471 sc-202471A | 5 g 50 g | $20.00 $42.00 | 4 | |
Aspirin could decrease CCL12 expression by irreversibly acetylating the enzyme cyclooxygenase, leading to a decrease in prostaglandin and thromboxane synthesis, thereby reducing the inflammatory stimuli for CCL12 gene expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 might inhibit CCL12 expression by blocking the c-Jun N-terminal kinase (JNK) pathway, which is involved in the activation of transcription factors that elevate CCL12 expression in response to inflammatory signals. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 may suppress the expression of CCL12 by selectively inhibiting MEK1 and MEK2, which are upstream activators of ERK1/2 in the MAPK pathway, thus reducing the transcriptional activity toward the CCL12 gene. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 could decrease the expression of CCL12 by specifically inhibiting p38 MAPK, which, when activated, promotes the production of numerous inflammatory cytokines, including CCL12, at the transcriptional level. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 may reduce CCL12 expression by inhibiting phosphoinositide 3-kinases (PI3K), thereby preventing Akt phosphorylation and subsequent activation of transcription factors responsible for CCL12 expression. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 might downregulate CCL12 expression by inhibiting IκBα phosphorylation, preventing the release and nuclear translocation of NF-κB, a key transcription factor that promotes CCL12 expression. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin has been shown to decrease CCL12 expression by inhibiting the activation of NF-κB and suppressing the inflammatory signaling cascades that are upstream triggers for CCL12 gene transcription. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin Gallate could inhibit CCL12 expression by hindering the phosphorylation and activation of transcription factors like NF-κB and AP-1, which are involved in the cellular responses that lead to increased CCL12 gene expression. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram may suppress CCL12 expression by selectively inhibiting phosphodiesterase 4 (PDE4), leading to an increase in intracellular cAMP levels, which in turn can inhibit the expression of inflammatory genes such as CCL12. | ||||||